Premium
Initial evaluation of pulmonary abnormalities: CT‐guided fine‐needle aspiration biopsy and fluoride‐18 fluorodeoxyglucose positron emission tomography correlation
Author(s) -
Collins Brian T.,
Lowe Val J.,
Dunphy Frank R.
Publication year - 2000
Publication title -
diagnostic cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.417
H-Index - 65
eISSN - 1097-0339
pISSN - 8755-1039
DOI - 10.1002/(sici)1097-0339(200002)22:2<92::aid-dc6>3.0.co;2-2
Subject(s) - medicine , radiology , biopsy , malignancy , fluorodeoxyglucose , positron emission tomography , lung , fine needle aspiration , lung cancer , nuclear medicine , pathology
Fluoride‐18 fluorodeoxyglucose positron emission tomography (FDG‐PET) can evaluate patients with new pulmonary lesions. CT‐guided fine‐needle aspiration (FNA) biopsy is a well‐described method in the diagnosis of pulmonary lesions. In order to correlate results from these testing modalities, retrospective findings from FNA biopsies of pulmonary lesions are compared to concurrent FDG‐PET scans. Files of the Saint Louis University Hospital were retrospectively searched for patients with CT‐guided FNA biopsies of the lung during a consecutive 3‐yr period. Patients were collected, and corresponding FDG‐PET scans were identified. Only new pulmonary lesions presenting for initial evaluation were included. Findings were correlated. Forty patients with a total number of 41 CT‐guided FNA biopsies of the lung and thoracic cavity had corresponding FDG‐PET scans. The combined positivity of the two testing modalities, i.e., cases where both FNA and FDG‐PET scan were positive, yielded a sensitivity of 100% (37/37). Four patients had infectious/inflammatory processes by CT‐guided FNA biopsy that were FDG‐PET‐positive for malignancy. CT‐guided FNA biopsies with FDG‐PET scans of pulmonary lesions are important, complementary diagnostic tools which can contribute significantly to the management and treatment of pulmonary disease. Diagn. Cytopathol. 2000;22:92–96. © 2000 Wiley‐Liss, Inc.